Hunter Cancer Research Alliance

As a multidisciplinary and multi-institutional alliance, the Hunter Cancer Research Alliance (HCRA) functions to provide capacity building, funding and strategic support to cancer research across the translational research continuum – from basic research through clinical trials to behavioural, implementation and health services research.

With the support of our partnering institutions, executive leaders and a membership that consists of 250+ cancer-focused researchers, we are working to promote the excellence of cancer research in the Hunter and ultimately improve cancer patient outcomes in our region and beyond.

HCRA Director, Professor Stephen Ackland, explains the work of HCRA in the video below:


Health Education Research Advance Access

The association between cannabis use and motivation and intentions to quit tobacco within a sample of Australian socioeconomically disadvantaged smokers

Laura Twyman1, Billie Bonevski, Christine Paul, Frances J. Kay-Lambkin, Jamie Bryant, C. Oldmeadow, K. Palazzi4 and A. Guillaumier


This study aimed to (i) describe concurrent and simultaneous tobacco and cannabis use and (ii) investigate the association between cannabis use and motivation and intentions to quit tobacco in a sample of socioeconomically disadvantaged smokers. A cross-sectional survey was conducted in 2013 and 2014 with current tobacco smokers
receiving aid fromtwo community service organizations in New South Wales, Australia. At least weekly cannabis use for the month prior to survey, motivation to quit tobacco and intentions to quit tobacco were measured in 369 participants (77% consent rate). Regressions were carried out to investigate associations between weekly cannabis use and motivation and intentions to quit tobacco.

Concurrent tobacco and cannabis use was reported by 19%(n¼71) of the sample and of these users, 100% reported simultaneous use. Although regular cannabis use was significantly associated with lower motivation to quit tobacco, it was not significantly associated with intentions to quit tobacco in the next 30 days. Concurrent
cannabis use is common in disadvantaged smokers and may play a role in decreasedmotivation to quit tobacco; however, it does not appear to be associated with intentions to quit in a sample of disadvantaged smokers.

Read the full article (PDF 117KB)

February: Thompson, E.R. et al (2016) Panel Testing for Familial Breast Cancer: Calibrating the Tension between Research and Clinical Care. Journal of Clinical Oncology 10.1200/JCO.2015.63.7454.

March: Bailey, P. et al (2016) Genomic analysis identify molecular subtypes of pancreatic cancer. Nature 532:47-52 doi 10.1038/nature16965

April: Hall, A.E. et al (2016) To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients. Critical Reviews in Oncology/hematology 97:247-262.

May: Twyman, L. et al (2016) Electronic Cigarettes: Awareness, Recent Use, and Attitudes within a sample of Socioeconomically disadvantaged Australian Smokers. Nicotine & Tocacco Research 18(5):670-677

June: Tracey, E et al (2016) How can we ensure that people with lung cancer living in rural and remote areas are treated surgically when appropriate. Medical Journal of Australia 204(9): 330-330.e1

July: Smith, A.M. et al (2016) Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget, Advanced Publications 2016

August: Faulkner, S. et al (2016) ProNGF is a potential diagnostic biomarker for thyroid cancer. Oncotarget 7(19): 28488-28497.

September: Goulooze. S.C. et al (2016) Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours. Cancer Chemother Pharmacol (2016) 78:209-2016.

October: Kristen McCarter et al (2016) Smoking cessation care among patients with head and neck cancer: a systematic review. BMJ Open 2016 6:e012296 doi:10.1136/bmjopen-2016-012296

November: Vahid Heravi Shargh et al (2016) Albumin Hybrid Nanoparticles Loaded with Tyrosine Kinase A Inhibitor GNF-5837 for Targeted Inhibition of Breast Cancer Cell Growth and Invasion. International Journal of Pharmaceutics.

The University of Newcastle, Australia Hunter New England Local Health District Calvary Mater Newcastle Hunter Medical Research Institute Cancer Institute NSW